Pawel Kalinski, MD, PhD, is Vice Chair of Translational Research at the Magee-Women’s Research Institute and a Professor of OBGYN and Immunology at the University of Pittsburgh School of Medicine. Dr. Kalinski is a graduate of the Medical University of Warsaw, Poland (MD) and the University of Amsterdam, Netherlands (PhD; Immunology). He served as a tenured Professor of Surgery and the Founding Director of the ImmunoTransplantation Center of the University of Pittsburgh Cancer Institute, and Senior Vice President for Team Science, Chair of Department of Immunology, and Chief of Translational Immuno-Oncology at Roswell Park Comprehensive Cancer Center in Buffalo, NY. His research focuses on the interplay between the activators of innate immunity (Interferons, TLR-Ligands, CTL/NK-attracting chemokines) and suppressive factors (prostanoids, suppressive cytokines, checkpoints, Treg/MDSC-attractants) in the regulation of tumor-specific responses. Dr. Kalinski and his laboratory and clinical partners develop 1) Cell-based therapies of cancer with focus on dendritic cell (DC) therapies (DC vaccines, intratumoral live adjuvants) and adoptive cell therapies (ACT) using DC-instructed T cells which recognition of cancer cells via TCR and NKRs; and 2) Therapeutic reprogramming of tumor microenvironments (TME) to enhance local infiltration of immune cells and enhance the therapeutic effectiveness of immune checkpoint inhibitors (ICI), ACT and other cancer treatments. Dr. Kalinski has authored over 160 scientific publications and 16 INDs and partnered with clinical faculty partners in the development of multiple early-phase clinical trials in melanoma, breast, ovarian, brain, prostate and colon cancers, supported by federally funded multi-institutional Team Science grants (MPI R01s, P01s, SPOREs) His work has been funded by over $50M in peer-reviewed federal grants from the National Cancer Institute (NIH/NCI), Department of Defense Congressionally Directed Medical Research Program (DoD/CDMRP), NY State, philanthropy, biotech and pharma partners. He has served on boards of directors and editorial boards of several professional organizations and scientific journals, and as a scientific consultant, editorial board member and reviewer for multiple grant-funding agencies and scientific journals in the United States and Europe.